Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Down 18.6% in May

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 145,200 shares, a decrease of 18.6% from the April 30th total of 178,300 shares. Currently, 18.9% of the company’s stock are short sold. Based on an average daily volume of 123,900 shares, the short-interest ratio is presently 1.2 days.

Analysts Set New Price Targets

ALZN has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Alzamend Neuro to a “sell” rating in a research note on Saturday. Ascendiant Capital Markets reduced their target price on shares of Alzamend Neuro from $288.00 to $180.00 and set a “buy” rating for the company in a research note on Monday, March 17th.

Alzamend Neuro Stock Down 8.6%

Shares of NASDAQ ALZN opened at $3.50 on Tuesday. Alzamend Neuro has a 1-year low of $3.06 and a 1-year high of $135.54. The company has a fifty day moving average price of $5.98 and a 200 day moving average price of $8.51.

Alzamend Neuro (NASDAQ:ALZN) last posted its quarterly earnings data on Monday, March 10th. The company reported ($1.71) EPS for the quarter, topping analysts’ consensus estimates of ($2.61) by $0.90. As a group, sell-side analysts forecast that Alzamend Neuro will post -1.68 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC acquired a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned about 0.56% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is currently owned by institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.